Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
CUE on Nasdaq
Shares outstanding
43,411,663
Price per share
$0.31
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
18,058,960
Total reported value
$12,982,249
% of total 13F portfolios
0%
Share change
+723,240
Value change
+$519,709
Number of holders
52
Price from insider filings
$0.31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Bleichroeder LP 10% 0% $5,269,789 6,127,662 0% Bleichroeder LP 19 Mar 2025
STROME MARK E 5% $1,862,968 2,166,242 Mark E. Strome 14 Nov 2022
Slate Path Capital LP 1.4% $790,199 918,836 Slate Path Capital LP 31 Dec 2024

As of 30 Sep 2025, 52 institutional investors reported holding 18,058,960 shares of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE). This represents 42% of the company’s total 43,411,663 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bleichroeder LP 16% 6,819,164 0% 0.96% $4,900,933
GC Wealth Management RIA, LLC 7.9% 3,431,644 +3% 0.08% $2,466,323
VANGUARD GROUP INC 7% 3,039,322 -4.6% 0% $2,185,273
GEODE CAPITAL MANAGEMENT, LLC 1.8% 800,768 +16% 0% $575,604
BOOTHBAY FUND MANAGEMENT, LLC 1.4% 610,964 0.01% $439,100
Robertson Stephens Wealth Management, LLC 1.1% 478,500 0% 0.01% $343,898
BlackRock, Inc. 1% 449,162 0% 0% $322,813
BANK OF AMERICA CORP /DE/ 0.75% 324,521 -0.02% 0% $233,005
ADVISORY RESEARCH INC 0.59% 257,225 0% 0.02% $184,868
RENAISSANCE TECHNOLOGIES LLC 0.52% 227,064 +70% 0% $163,191
UBS Group AG 0.46% 199,158 -32% 0% $143,195
STIFEL FINANCIAL CORP 0.45% 196,556 0% 0% $141,265
STATE STREET CORP 0.44% 189,753 0% 0% $136,375
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.38% 166,456 +7.9% 0% $119,632
ANGELES WEALTH MANAGEMENT, LLC 0.28% 120,000 0% 0.01% $86,244
NORTHERN TRUST CORP 0.23% 100,958 -24% 0% $72,559
Chicago Partners Investment Group LLC 0.2% 85,937 -2.7% 0% $63,466
Squarepoint Ops LLC 0.2% 85,800 0% $61,664
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 0.18% 79,500 -4.2% 0% $57,136
Sigma Planning Corp 0.12% 53,300 -4% 0% $38,307
LPL Financial LLC 0.11% 46,390 -22% 0% $33,340
TWO SIGMA SECURITIES, LLC 0.09% 39,514 0% $28,399
Texas Capital Bank Wealth Management Services Inc 0.08% 33,102 0% 0% $23,790
MORGAN STANLEY 0.06% 27,512 -6.6% 0% $19,773
Navalign, LLC 0.06% 25,000 0% 0% $17,968

Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,120 $5,739 -$719 $0.31 3
2025 Q3 18,058,960 $12,982,249 +$519,709 $0.72 52
2025 Q2 17,351,508 $11,856,298 +$3,983,649 $0.68 46
2025 Q1 11,402,706 $10,374,424 -$452,161 $0.91 49
2024 Q4 11,759,494 $12,816,995 -$1,528,241 $1.09 55
2024 Q3 13,910,388 $10,533,734 -$288,922 $0.76 50
2024 Q2 13,807,875 $17,121,019 -$3,730,383 $1.24 72
2024 Q1 16,387,055 $30,971,606 +$2,715,659 $1.89 74
2023 Q4 14,886,167 $39,304,464 +$2,537,424 $2.64 80
2023 Q3 14,014,675 $32,148,839 -$634,604 $2.30 75
2023 Q2 13,849,849 $50,545,862 +$6,687,288 $3.65 77
2023 Q1 12,055,434 $43,037,472 -$2,540,576 $3.57 62
2022 Q4 12,761,302 $36,370,518 +$155,907 $2.85 60
2022 Q3 12,797,287 $28,665,093 -$2,995,285 $2.23 61
2022 Q2 14,083,808 $35,042,763 -$10,988,434 $2.49 68
2022 Q1 17,812,661 $87,010,965 +$4,491,451 $4.88 97
2021 Q4 16,533,577 $187,228,947 -$11,058,319 $11.31 88
2021 Q3 16,892,813 $245,597,815 -$23,967,610 $14.57 87
2021 Q2 18,582,224 $216,368,968 -$2,774,327 $11.65 89
2021 Q1 18,817,560 $229,653,033 -$6,452,286 $12.20 88
2020 Q4 19,314,982 $241,658,115 -$3,019,434 $12.51 94
2020 Q3 19,517,235 $293,948,076 +$49,950,366 $15.05 90
2020 Q2 16,042,165 $393,156,090 +$84,955,728 $24.51 99
2020 Q1 13,033,369 $184,956,981 +$36,613,314 $14.19 72
2019 Q4 10,554,208 $167,568,706 +$63,118,277 $15.88 60
2019 Q3 6,080,606 $51,262,809 +$13,288,944 $8.43 44
2019 Q2 4,501,012 $40,453,546 +$9,997,120 $8.99 36
2019 Q1 3,453,175 $26,693,413 +$1,831,681 $7.73 37
2018 Q4 3,229,210 $15,171,419 -$2,037,779 $4.70 34
2018 Q3 3,579,962 $32,396,140 +$3,237,621 $9.05 36
2018 Q2 3,148,586 $37,344,175 +$15,445,827 $11.86 37
2018 Q1 1,844,607 $25,915,405 +$25,915,405 $14.05 28